Strategies to combat multi-drug resistance in tuberculosis
Conspectus “Drug resistance is an unavoidable consequence of the use of drugs; however,
the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor …
the emergence of multi-drug resistance can be managed by accurate diagnosis and tailor …
[HTML][HTML] Biological activity of oxadiazole and thiadiazole derivatives
UA Atmaram, SM Roopan - Applied Microbiology and Biotechnology, 2022 - Springer
The 5-membered oxadiazole and thiadiazole scaffolds are the most privileged and well-
known heterocycles, being a common and essential feature of a variety of natural products …
known heterocycles, being a common and essential feature of a variety of natural products …
Recent advances of pyrazole-containing derivatives as anti-tubercular agents
Z Xu, C Gao, QC Ren, XF Song, LS Feng… - European journal of …, 2017 - Elsevier
One-third of the world's population infected tuberculosis (TB), and more than 1 million
deaths annually. The co-infection between the mainly pathogen Mycobacterium tuberculosis …
deaths annually. The co-infection between the mainly pathogen Mycobacterium tuberculosis …
[HTML][HTML] A rich gallery of carbon dots based photoluminescent suspensions and powders derived by citric acid/urea
JD Stachowska, A Murphy, C Mellor, D Fernandes… - Scientific reports, 2021 - nature.com
In this study we demonstrate simple guidelines to generate a diverse range of fluorescent
materials in both liquid and solid state by focusing on the most popular C-dots precursors, ie …
materials in both liquid and solid state by focusing on the most popular C-dots precursors, ie …
Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery
D Bald, C Villellas, P Lu, A Koul - MBio, 2017 - Am Soc Microbiol
Drug-resistant mycobacterial infections are a serious global health challenge, leading to
high mortality and socioeconomic burdens in developing countries worldwide. New …
high mortality and socioeconomic burdens in developing countries worldwide. New …
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
A Campaniço, R Moreira, F Lopes - European journal of medicinal …, 2018 - Elsevier
Tuberculosis (TB) remains a major health problem worldwide. The infectious agent,
Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating …
Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating …
Pyrazolo[1,5-a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis
Respiration is a promising target for the development of new antimycobacterial agents, with
a growing number of compounds in clinical development entering this target space …
a growing number of compounds in clinical development entering this target space …
[HTML][HTML] The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd
Mycobacterial energy metabolism currently attracts strong attention as new target space for
development of anti-tuberculosis drugs. The imidazopyridine Q203 targets the cytochrome …
development of anti-tuberculosis drugs. The imidazopyridine Q203 targets the cytochrome …
Marine natural products with anti-inflammatory activity
RCF Cheung, TB Ng, JH Wong, Y Chen… - Applied microbiology and …, 2016 - Springer
Chronic inflammation is believed to play crucial roles in the pathogenesis of various
diseases. Several types of drugs are used to treat inflammatory disorders, but they cause …
diseases. Several types of drugs are used to treat inflammatory disorders, but they cause …
[HTML][HTML] Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis
New drugs with new mechanisms of action are urgently required to tackle the global
tuberculosis epidemic. Following the FDA-approval of the ATP synthase inhibitor …
tuberculosis epidemic. Following the FDA-approval of the ATP synthase inhibitor …